Platform for identifying novel analgesic therapies
AssigneeEptiva Therapeutics Ltd.
InventorMark J. FIELD
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to a platform for linking therapeutic compounds to pain phenotypes/conditions and thereby identifying potential novel analgesic therapies. The platform can generate patient selection criteria and/or identify a subset of patients that would be suitable for a clinical trial related to the selected therapeutic compound and the one or more identified pain phenotypes/conditions.
Claims19
A system configured to link a therapeutic compound to one or more pain phenotypes or conditions, the system comprising:
- one or more processors;
- and
- one or more hardware storage devices having stored thereon computer-executable instructions which are executable by the one or more processors to cause the system to at least:
- receive a selected therapeutic compound;
- generate a protein-protein interaction map for each of one or more parameter settings for the selected therapeutic compound;
- for each parameter setting generate a set of predicted gene pathways based on the corresponding protein-protein interaction map, and
- generate a set of pain phenotype associations based on the protein-protein interaction map and the set of predicted gene pathways;
- combine the sets of pain phenotype associations from each parameter setting;
- identify one or more pain phenotypes having sufficient overlap across the combined sets of pain phenotypes associations as potential treatment targets;
- and
- identify the selected therapeutic compound as a potential analgesic for the one or more potential treatment targets.
A computer-implemented method for linking a therapeutic compound to one or more pain phenotypes or conditions, the method comprising:
- receiving a selected therapeutic compound;
- generating a protein-protein interaction map for each of one or more parameter settings for the selected therapeutic compound;
- for each parameter setting
- generating a set of predicted gene pathways based on the corresponding protein-protein interaction map, and
- generating a set of pain phenotype associations based on the protein-protein interaction map and the set of predicted gene pathways;
- combining the sets of pain phenotype associations from each parameter setting;
- identifying one or more pain phenotypes having sufficient overlap across the combined sets of pain phenotype associations as potential treatment targets;
- and
- identifying the selected therapeutic compound as a potential analgesic for the one or more potential treatment targets.
Dependencies are inferred from the claim text.